UCB stock: FDA approves ZILBRYSQ autoinjector before Xetra open
Published on 10/21/2026 at 07:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSFDA approval for treatment option
- FDA approved an autoinjector option for ZILBRYSQ on October 20, 2026.
- UCB’s investor materials describe its 2026 medicines as addressing neurological and immunological diseases.
- UCB stock trades pre-market at EUR 218.90 at 7:52 a.m. CEST at Lang & Schwarz on October 21, 2026.
On October 20, 2026, UCB announced that the U.S. Food and Drug Administration had approved a self-administered autoinjector option for ZILBRYSQ in adults with generalized myasthenia gravis, according to PR Newswire. UCB stock trades pre-market at EUR 218.90 at 7:52 a.m. CEST at Lang & Schwarz on October 21, 2026.
UCB outlines the FDA decision
The approval adds a once-daily autoinjector to the existing prefilled-syringe option for eligible adults who are anti-acetylcholine receptor antibody positive. UCB said complete dose delivery was achieved for 99.8 percent of 449 autoinjector administrations in supporting study data. The company expects commercial availability in the first quarter of 2027, according to PR Newswire.
Ahead of the Xetra open
The pre-market indication is available in Berlin trading ahead of the Xetra session. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of UCB stock.
UCB’s medicines and market
UCB develops and commercializes medicines for people living with severe neurological and immunological diseases, according to its investor materials. The company’s 2026 portfolio includes treatments and development programs in both areas, as described by UCB. Market context: Market report Euro Stoxx 50.
